Managing Supply For Complex Biotherapeutics
By Iwan Bertholjotti, Director Commercial Development Bioconjugates, Lonza, Visp, Switzerland

Antibody-drug conjugates (ADCs) are complex bioconjugates typically used as vector-based chemotherapy, allowing the selective delivery of a nanomolar potent cytotoxic agent within a tumor. For drug substance manufacturing, the cytotoxic agent and the targeted monoclonal antibody are chemically linked via a linker. The drug product for an ADC is typically filled and lyophilized to distribute the drug in a stable form.
ADCs are complex, and their manufacturing supply chain contains five different technologies with specific asset needs: monoclonal antibody, cytotoxic payload, linker, bioconjugation and fill & finish. Even with the necessary expertise, the combination of disparate technology requirements to manufacture the five ADC components creates supply complexity. It can take years of effort to establish a reliable, high-performing logistics network to manufacture ADCs. Many companies, therefore, consider outsourcing to experienced contract development and manufacturing organizations (CDMOs) as an option to accelerate development and limit risk.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.